跳至主要内容
临床试验/NCT05243433
NCT05243433已完成不适用

Maestro LIFT-OFF: A Feasibility, Prospective, Single Center, Single-arm Study of the Maestro Surgical Assistance Device in Abdominal Laparoscopic Surgery

Moon Surgical1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2022年4月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
50
试验地点
1
主要终点
Completion of the procedure using the Maestro Platform without conversion to a manual minimally invasive or open surgical procedure specifically due to a device failure or malfunction

研究概览

简要总结

The objective of the study is to provide evidence for the safety and effectiveness of the Maestro Platform for surgical assistance in abdominal laparoscopic surgery.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age: ≥ 18 to ≤ 75 years
  • Scheduled for one of the following non-emergent laparoscopic procedure: cholecystectomy, hernia repair, appendectomy, bariatric surgery (gastric sleeve or gastric bypass), or colectomy.
  • Willing to comply with protocol-specified follow-up evaluation
  • Signed informed consent

排除标准

  • Advanced refusal of blood transfusion, if necessary;
  • Active systemic or cutaneous infection or inflammation;
  • Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;
  • Uncontrolled diabetes mellitus;
  • Known, significant history of bleeding diathesis, or coagulopathy, or Von Willebrand's disease or current platelet count < 100,000 cells/mm3, or baseline INR ≥1.8, or fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24 hours);
  • Severe co-existing morbidities having a life expectancy of less than 30 days;
  • Currently participating in another investigational drug or device study that clinically interferes with the endpoints of this study;
  • Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than 30%;
  • Renal insufficiency (serum creatinine of > 2.5 mg/dl);
  • Females who are pregnant, planning to become pregnant within three months of the procedure, or lactating;
  • Extreme morbid obesity (BMI greater than 45 kg/m2);
  • Patients presenting with ascites;
  • Patients presenting for emergency surgery;
  • Previous surgery in the same anatomical location;
  • Lack of capacity to give informed consent (individuals deprived of their liberty subject to a legal protection measure or who are unable to express their consent, individuals under guardianship or curatorship)

结局指标

主要结局

Completion of the procedure using the Maestro Platform without conversion to a manual minimally invasive or open surgical procedure specifically due to a device failure or malfunction

时间窗: During procedure

Adverse Events (AEs) in terms of type (device/procedure related), seriousness, level of severity. Rate of occurence of intra-procedural and post-procedural adverse events, and device related complications

时间窗: 30 days

次要结局

未报告次要终点

研究者

发起方
Moon Surgical
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验